Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
about
Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy.Ischemic maculopathy following intravitreal bevacizumab for refractory diabetic macular edema.Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy.Changes in Retinal Nerve Fiber Layer Thickness after Two Intravitreal Bevacizumab Injections for Wet Type Age-related Macular Degeneration.Insight into 144 patients with ocular vascular events during VEGF antagonist injectionsAnalysis of Potential Ischemic Effect of Intravitreal Bevacizumab on Unaffected Retina in Treatment-Naïve Macular Edema Due to Branch Retinal Vein Occlusion: A Prospective, Interventional Case-SeriesTreatment of diabetic retinopathy with anti-VEGF drugs.Bevacizumab prior to vitrectomy for diabetic traction retinal detachment.Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology.Intravitreal Bevacizumab with or without Triamcinolone for Refractory Diabetic Macular Edema: Long-term Results of a Clinical TrialExtract of Litsea japonica ameliorates blood-retinal barrier breakdown in db/db mice.Vision, retinal thickness, and foveal avascular zone size after intravitreal bevacizumab for diabetic macular edema.Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration.An Overview of Our Current Understanding of Diabetic Macular Ischemia (DMI)
P2860
Q30979491-D905EEF6-8742-448B-BE5C-9773BEE1F72BQ33695966-59CBD8D8-762D-4930-A532-A87F0CA1426AQ34474545-2514D841-E1AC-49CE-8CA1-6CA2EB7CFA7FQ35087028-2CD1235F-ED74-45C1-9AC9-CBD2923330C1Q35822200-BABA3B03-B8C5-4A68-BEEC-59A8B1872BF5Q36130147-A85FDE5E-AC50-4ED6-8BAB-2F6EC515F1A8Q37806321-831CF4DB-F02A-4B9A-885E-C25EC583FDC4Q38543178-1565F0FA-6DFD-4DCF-8121-3ADD1677AA4EQ41892388-2CB34E92-9F80-40FD-9D1A-A5254DC3218AQ42091540-AE35354F-E915-4D4A-A15A-26FF14A379E1Q44418091-B21B5DB3-6A12-4350-BF6F-EFD0F5B63CA8Q47322584-DD838BE6-334E-4201-82F7-834281ABF2B6Q51065961-BB5CCB59-B8FE-4E85-B852-45D62269B016Q57138230-99359643-1C31-449B-A9AF-CEC92AC70076
P2860
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
@ast
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
@en
type
label
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
@ast
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
@en
prefLabel
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
@ast
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
@en
P2093
P1476
Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema.
@en
P2093
P356
10.3928/15428877-20090101-04
P577
2009-01-01T00:00:00Z